Crossmark

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Crossref DOI link: https://doi.org/10.1136/jitc-2021-002863

Published Online: 2021-08-13

Published Print: 2021-08

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Piha-Paul, Sarina A https://orcid.org/0000-0001-9455-1660
Geva, Ravit

Tan, Tira J

Lim, Darren WT

Hierro, Cinta

Doi, Toshikiko

Rahma, Osama

Lesokhin, Alexander

Luke, Jason John https://orcid.org/0000-0002-1182-4908
Otero, Javier

Nardi, Lisa

Singh, Angad

Xyrafas, Alexandros

Chen, Xinhui

Mataraza, Jennifer

Bedard, Philippe L
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02740270 at ClinicalTrials.gov

Documents that mention this clinical trial

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
https://doi.org/10.1136/jitc-2021-002863

New emerging targets in cancer immunotherapy: the role of GITR
https://doi.org/10.1136/esmoopen-2020-000738

Targeting Cbl-b in cancer immunotherapy
https://doi.org/10.1136/jitc-2022-006007
Funding

Funding for this research was provided by:

Novartis
License Information

License valid from 2021-08-13

Document is current

Any future updates will be listed below